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Background On the basis of a retrospective survey by this unit it was suggested that patients with acute ventilatory failure should be given sufficient controlled oxygen treatment to raise the arterial oxygen tension (PaO2) to above 6-6 kPa, with the addition of a respiratory stimulant if the hydrogen ion concentration ([H+J) rose above 55 nmol/l and assisted ventilation if the patient remained acidotic despite these measures. This study was designed to verify the prognostic factors that determine survival in acute ventilatory failure and determine the outcome when our guidelines were implemented. Methods One hundred and thirty nine episodes of acute hypercapnic (type II) resiratory failure were studied prospectively in 95 patients admitted with acute exacerbations of chronic obstructive lung disease. Patients had to have a Pao2 below 6-6 kPa and an arterial carbon dioxide tension (Paco2) above 6-6 kPa while breathing air. Results The mortality associated with episodes of acute ventilatory failure was 12%. Patients who died tended to be older and were significantly more acidotic, hypotensive, and uraemic on admission than those who survived, but they had similar degrees of hypoxaemia and hypercapnia. Death occurred in 10 of the 39 episodes in which arterial [H+] rose to 55 nmol/l or above, compared with seven of the 100 episodes in which it remained below 55 nmol/l. The Although patients with chronic obstructive lung disease are frequently admitted to hospital with acute exacerbations of hypercapnic respiratory failure, there is disagreement about management of this condition and a lack of well documented criteria that are easily applied at the bedside to guide intervention. The frequency of use of assisted ventilation in patients with acute hypercapnic respiratory failure due to chronic obstructive lung disease`' has varied from 16% to 35% and the overall mortality from 19% to 29%. In studies combining patients with and without hypercapnia 3-65% have been ventilated, with an overall mortality of 6-34%."
In a retrospective study of 157 episodes of hypercapnic respiratory failure in 135 patients mortality increased with age and was highest in those with a hydrogen ion concentration [H+] of 55 nmol/l or more. 3 We suggested that supplemental oxygen treatment in these patients should be guided by the arterial oxygen tension (Pao2) and [H+] and that the aim should be to increase Pao2 above 6-6 kPa without causing the [H+] to rise to 55 nmol/l (fall in pH below 7 26). If [H+] rose higher and could not be lowered by adjustment of the inspired oxygen concentration a respiratory stimulant should be used, with assisted ventilation being reserved for patients remaining acidotic despite these measures.
To verify the previously identified prognostic factors for survival and to test the usefulness in practice of these guidelines, which were derived from data collected retrospectively, we prospectively studied 139 consecutive admissions in 95 patients suffering from acute respiratory failure due to chronic obstructive lung disease whose management was based on the guidelines. Venous blood was sampled on admission, on days 2 and 3 after admission, and before discharge. Samples were analysed for haemoglobin concentration, white cell count, and urea, electrolyte, and liver enzyme concentrations. )ncentration on sion (figure 2). Although there was no ates correction improvement in Paco2 at discharge or follow up se of hypnotics, in 10 episodes (figure 2), eight of these showed nce of raised an improvement in Pao2. 
Methods
the sternal angle) was recorded in 54 episodes (39%) and peripheral "flap" in 35 episodes on admission, but papilloedema was not observed in any episodes. Electrocardiographs were taken on admission in 83 cases, and 25 (30%) showed right ventricular hypertrophy (right axis deviation and R wave in Vl plus S wave in V6 > 10 mm).
PROGNOSTIC FACTORS FOR SURVIVAL
In 17 of the 139 episodes (12%) the patient died. The death rate in patients receiving supplemental oxygen before admission (four deaths in 16 episodes) was not significantly different from that in patients who were not (13 deaths in 123 episodes). The results for all 139 episodes were therefore combined for analysis except for arterial blood gas tensions and [H+] on admission.
Patients who died during the admission tended to be older than those who survived (table 1), but the difference was not significant. There was no relation between survival and Pao2 or PaCO2 on admission when breathing room air or haematological variables, plasma electrolyte values, and liver enzyme concentrations measured on admission (table 1). The incidence of right ventricular hypertrophy and a raised jugular venous pressure were also similar in those who survived and those who died (table 1) . Patients who died were, however, significantly more acidotic (figure 3) and uraemic and had a lower systolic blood pressure on admission than those who survived (table 1) .
Controlled oxygen treatment raised Pao2 above 6-6 kPa in 126 of the 139 episodes within 12 hours of admission. In the 126 episodes inspired oxygen was adjusted so that Pao2 was maintained between 6-6 kPa and a mean highest value of 8-8 (1-3) kPa (range 6-6-12-3 kPa). There was no significant relation between Pao2 or Paco2 at any time during the admission and survival.
Outcome was related to the severity of acidosis during the admission. Paco2 (kPa) 
Discussion
This study had two aims. The first was to verify the prognostic factors for survival in patients with acute hypercapnic respiratory failure due to chronic obstructive lung disease previously identified in a retrospective study. The second was to test whether the bedside guidelines for treatment in these patients derived from retrospective data3 were useful in clinical practice.
Inclusion of patients in the study was based on arterial blood gas tensions. Acute exacerbations of the disease were identified when there were reported increases in cough, purulent sputum production, and dyspnoea. The lower Pao2 and higher Paco2 values on admission compared with those before discharge or at follow up support the clinical evidence that the patients had an acute exacerbation of their chronic condition.
The results confirm the relation between a high arterial [H +] (low arterial pH) and increased mortality.2"9 As in our earlier study,3 The patients who died had significantly higher blood urea concentrations and lower systolic blood pressures on admission than those who survived, a finding also noted in patients with community acquired pneumonia.'4 These findings probably reflect the severity of systemic disturbance associated with an exacerbation as there was no evidence of a significant metabolic acidosis associated with either the raised urea concentration or poor tissue perfusion (figure 3). Although previous studies by us' and others4 have shown an increase in death rate with age, the patients who died in the present study tended to be older than those who survived, but the difference was not significant.
The guidelines derived from the retrospective study proposed that a respiratory stimulant such as doxapram should be used if [H+ ] rose to 55 nmol/l or more while the patient was being given oxygen treatment, with assisted ventilation being considered only when this regimen failed to reduce the acidosis. These guidelines were not followed rigorously as the degree of acidosis occurred only transiently in some patients and in others respiratory stimulant treatment was believed by the attending physician to be indicated clinically before severe acidosis had developed. We combined the data from all patients who had received doxapram to allow us to study the effect of the treatment as it was used. It is not possible to prove whether systematic use of a respiratory stimulant contributed directly to the lower mortality of 12% recorded in this study compared with the rate of 20% in the retrospective series.' An overall mortality of 30% in the 37 episodes treated with doxapram (table 2) seems high, but these patients were selected for doxapram treatment because they had severe respiratory acidosis and their risk of death was therefore high. As episodes may have been unrelated to the doxapram treatment, but the response is consistent with the effect of doxapram seen in a placebo controlled trial in similar patients.' Although respiratory stimulants were used in a similar proportion of episodes in this study (27%) and our retrospective series (29%),3 many of the patients in the earlier study were given intermittent nikethamide rather than a continuous infusion of doxapram and respiratory stimulants tended to be used as a last resort in patients considered to be unsuitable for assisted ventilation. In the present study use of doxapram in a fairly systematic manner based on objective starting criteria may have contributed to the low mortality rate, but this is difficult to prove.
Other treatments were similar in the two studies except for the use of nebulised f2 agonists in this but not the earlier series. Whether this may also have contributed to the improved survival rate, is impossible to say. Patients taking oral steroids had a slightly lower mortality, probably reflecting the fact that they had been selected, when their condition was stable, as having a slightly larger reversible component to their airways obstruction. The response of such patients in an exacerbation may differ from the response of those not taking steroids, but we cannot say whether the routine use of corticosteroids is helpful in episodes of acute ventilatory failure.
In this study, episode death rate was 12%, and assisted ventilation was used in only four episodes (3%). Mortality in previous studies has ranged from 6% to 34% and use of assisted ventilation from 3% to 65%.'-" Direct comparison of rates between studies is difficult as the criteria for inclusion of patients has varied, objective criteria have not always been quoted,9 " and not all patients have had type II respiratory failure due to chronic obstructive lung disease.4'0 Other studies, including our retrospective study, were restricted to patients with type II respiratory failure due to chronic obstructive lung disease and report rates of between 19% and 29%.'`' The death rate in the present study is therefore lower than that previously reported in similar patients despite minimal use of assisted ventilation. Our emphasis on raising Pao2 above 6-6 kPa with controlled low flow oxygen treatment was generally achieved and may have contributed to the successful outcome compared with our earlier study.' However, data are insufficient on the degree of oxygenation achieved in our previous study to determine this.
In previous series the decision to 
